Equity Research Medical Devices

Should You Buy Vivos Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Vivos Inc. (RDGL) carries a solid Quality of Company rating of 6.4/10. Trading at $0.05, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 1 CirclFi valuation models project upside for Vivos Inc. (RDGL) at $0.05 — the model consensus leans bearish, with a Quality Score of 6.4/10 and Value-Trap risk of 22/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 6.4/10 — Moderate — mixed signals
  • Value Trap Risk: 22/100 — Minimal — healthy fundamentals
  • Fair Value Range: $0.01 – $0.01 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

6.4 /10

Moderate — mixed signals

Value Trap Risk

22 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

1 /13
Active Models

Avg. confidence: 51%

What Is the Investment Case for Vivos Inc. (RDGL) in 2026?

What Is the Bull Case vs the Bear Case for Vivos Inc. (RDGL)?

Bull case versus bear case for Vivos Inc. (RDGL) at $0.05, derived from 1 active CirclFi valuation models on 2026-08-27.
Bull case Bear case — $0.01 target (-89.1%)
No active model projects meaningful upside for RDGL at $0.05. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.01 (-89.1%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: regulatory rejection risk represents a meaningful risk for Vivos Inc. and its Medical Devices peers.

How Does RDGL Compare to Its Medical Devices Peers?

BFLY Butterfly Network, I
6.4
ECOR electroCore, Inc.
6.4
TNDM Tandem Diabetes Care
6.5
APYX Apyx Medical Corpora
6.3
RXST RxSight, Inc.
6.5
PETV PetVivo Holdings, In
6.3
INBS Intelligent Bio Solu
5.4
RTGN RetinalGenix Technol
3.5

Valuation data pages: BFLY · ECOR · TNDM · APYX · RXST · PETV · INBS · RTGN · SIBN · IRMD · PODD

See full Medical Devices rankings →

Which Other Stocks Score Like RDGL on Quality?

Closest companies to RDGL’s Quality of Company score of 6.4/10, across all industries.

Which Medical Devices Screens Does RDGL Appear In?

Why Do CirclFi’s 1 Models Disagree on RDGL?

Spread

0%

Fair Value Range

$0.01 – $0.01

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Dynamic NAV

$0.01 (-89.1%)

Most Bearish

Dynamic NAV

$0.01 (-89.1%)

What Are the Biggest Risks of Buying RDGL Stock?

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View RDGL Data Page →

So Is Vivos Inc. (RDGL) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Vivos Inc. at $0.05. 1/1 models flag overvaluation, median fair value sits at $0.01 (-89.1%), and the risk-reward profile appears unfavorable. Quality at 6.4/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Vivos Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About RDGL Stock?

Should I buy RDGL stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for RDGL at $0.05. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Vivos Inc.?

Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does RDGL compare to its competitors?

Among Medical Devices peers, RDGL holds a Quality Score of 6.4/10. Comparable companies include BFLY (QOC 6.4), ECOR (QOC 6.4), TNDM (QOC 6.5). The relative ranking helps investors identify whether RDGL offers better fundamental quality than alternatives in the same sector.

Is RDGL a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RDGL's Quality Score of 6.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy RDGL at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.01 to $0.01. At $0.05, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for RDGL.

View RDGL Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →